null

null

null

null

null

null

null

null

null

Minimal debt; BioCardia is a pre-revenue clinical-stage company funded primarily by equity; near-zero leverage ratio.

Negligible direct debt interest sensitivity; higher rates increase cost of future equity/debt raises and compress biotech valuations.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Catheter and biologic component manufacturing concentrated in U.S. and potentially Taiwan/China for precision medical device components.

Essentially no international revenue; U.S.-centric clinical trials mean sovereign currency devaluation exposure is near-zero currently.

Predominantly U.S.-based operations; no meaningful international commercial footprint; currency devaluation exposure is negligible.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single-source suppliers for proprietary helical infusion catheter components; substitution would require FDA revalidation.

Cloud disruption risk is low; core operations are lab/clinical-based; EHR and trial management software could be disrupted but are not mission-critical cloud-native.

Clinical-stage biopharmaceutical/medical device hybrid; revenue model is pre-commercial grant and licensing-dependent.

Low API coupling risk; BioCardia uses standard clinical and regulatory software; no proprietary API dependencies identified.

Low Howey risk; revenue derives from grants and licensing of medical technology, not investment contracts or token-like instruments.

Very High

Moderate HIPAA exposure from clinical trial patient data; limited GDPR/CCPA risk given minimal non-U.S. patient enrollment currently.

Low antitrust risk; niche cardiac regenerative therapy market; no dominant market position or exclusionary conduct identified.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Primarily transactional/grant-based; no recurring subscription revenue; milestone and licensing payments are episodic, not contractually recurring.

Licensing fees, NIH/NHLBI grants, and potential future per-procedure or device sales upon FDA approval.

No commercial pricing architecture yet; future pricing will benchmark against cardiac surgery and competing cell therapy procedures (~$50K–$150K range).

Moderate potential pricing power if clinical trials succeed; novel regenerative therapy with limited direct competition justifies premium positioning.

Target gross margin likely 60–75% at commercial scale for biologic/device combination products, assuming contract manufacturing.

No free-rider problem; proprietary catheter delivery system and cell therapy create high barriers; no open-source equivalent exists.

Headcount-linear at current stage; revenue scaling post-approval would require proportional clinical, manufacturing, and sales staff additions.

High marginal cost of growth; each trial expansion and commercial launch requires significant capital, headcount, and regulatory investment.

Not applicable; BioCardia does not operate a franchise model.

At 10x scale, CAC would be dominated by hospital/cardiology network contracting; estimated sales cycle 12–18 months per institution.

No meaningful network effects; adoption is driven by clinical evidence, not user-base size; no platform dynamics present.

9.4% Return on Assets (Excellent)

Low recession resistance; elective cardiac procedures decline in downturns; reimbursement and hospital capital budgets are cyclically sensitive.

U.S. academic medical centers and large cardiac surgery programs as initial commercial targets; high concentration risk.

NIH and NHLBI as grant-funding customers; heavy reliance on federal funding creates political/budget concentration risk.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital is being deployed into clinical trials and GMP manufacturing development; no legacy infrastructure reallocation; forward-looking spend dominates.

0000925741

BCDA